Diffusion-weighted MR Imaging in Monitoring the Effect of a Vascular Targeting Agent on Rhabdomyosarcoma in Rats

This publication has 27 references indexed in Scilit:

• Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging
  Journal of Clinical Oncology, 2003
• Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
  Journal of Clinical Oncology, 2003
• Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
  Journal of Clinical Oncology, 2003
• The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
  International Journal of Oncology, 2002
• The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
  Blood, 2002
• Evaluation of the anti‐vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI
  NMR in Biomedicine, 2002
• Differential sensitivity of two adenocarcinoma xenografts to the anti‐vascular drugs combretastatin A4 phosphate and 5,6‐dimethylxanthenone‐4‐acetic acid, assessed using MRI and MRS
  NMR in Biomedicine, 2002
• The biology of the combretastatins as tumour vascular targeting agents
  International Journal of Experimental Pathology, 2002
• Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
  British Journal of Cancer, 1998
• Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
  The British Journal of Radiology, 1993